Dermatomyositis
Drug research and approvals for dermatomyositis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 47 studies of dermatomyositis are recruiting on ClinicalTrials.gov, Health Canada has authorized 4 drug trials for it since 2013, and FDA has 2 approved and 9 open orphan designations naming it.
- Recruiting worldwide: 47
- Trials authorized in Canada: 4
- FDA orphan approvals: 2
- EU medicines: 0
- FT839 in Autoimmune DiseasesNCT07800871 · Phase 1 / Phase 2 · Fate Therapeutics · starts Oct 1, 2026
- BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory MyopathyNCT07715136 · Phase 1 · iCell Gene Therapeutics · starts Mar 20, 2025
- Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune…NCT07558850 · Not applicable · The First Affiliated Hospital with Nanjing Medical University · starts May 10, 2026
- Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) StudyNCT07486869 · Phase 2 · University of Miami · starts Jul 23, 2026
- A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101NCT07403188 · Not reported · Kyverna Therapeutics · starts Nov 24, 2025
- Descartes-08 in Autoantibody MyositisNCT07391605 · Phase 2 · Cartesian Therapeutics · starts Apr 28, 2026
- RCT of Tocilizumab for Anti-MDA5+DMNCT07377058 · Not applicable · Peking Union Medical College Hospital · starts Nov 1, 2025
- MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)NCT07374107 · Not reported · Myositis International Health & Research Collaborative Alliance Foundation · starts Jun 25, 2025
- Panniculitis in DermatomyositisNCT07345949 · Not reported · University Hospital, Strasbourg, France · starts Oct 20, 2025
Approved 1
- PrednisoneGlucocorticoid receptor agonist
Phase 3 9
- Human immunoglobulin gReplacement therapy, immunomodulatory effects
- AbataceptT-lymphocyte activation antigen CD86 inhibitor
- BaricitinibTyrosine-protein kinase JAK1 inhibitor
- MethotrexateDihydrofolate reductase inhibitor
- BrepocitinibTyrosine-protein kinase TYK2 inhibitor
- Lenabasum
- CyclosporineCyclophilin A modulator
- AldesleukinInterleukin-2 receptor agonist
- UstekinumabInterleukin-12 inhibitor
Phase 2 12 of 18
- EtanerceptTNF-alpha inhibitor
- SiponimodSphingosine 1-phosphate receptor Edg-1 agonist
- DazukibartInterferon beta inhibitor
- Zetomipzomib
- InfliximabTNF-alpha inhibitor
- EculizumabComplement C5 inhibitor
- RavulizumabComplement C5 inhibitor
- RituximabB-lymphocyte antigen CD20 binding agent
- TocilizumabInterleukin-6 receptor alpha subunit inhibitor
- MethimazoleThyroid peroxidase inhibitor
- AnakinraInterleukin-1 receptor antagonist
- CorticotropinMelanocortin receptor 2 agonist
Phase 1 or earlier 3
- TofacitinibJanus Kinase (JAK) inhibitor
- SifalimumabInterferon alpha inhibitor
- ItolizumabT-cell differentiation antigen CD6 inhibitor
How its trials ended
142 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 31 whose ending is known, 52% met their primary endpoint, 0% missed it and 48% stopped early.
- Ongoing4935%
- Completed, result not reported4230%
- Status unknown2014%
- Met its primary endpoint1611%
- Stopped: other or unclear64%
- Stopped: enrollment or feasibility43%
- Stopped: lack of efficacy21%
- Stopped: sponsor or business decision21%
- Stopped: funding11%
| Sep 7, 2022 | A phase 3, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of oral brepocitinib in adults with dermatomyositisBrepocitinib (PF-06700841) | Priovant Therapeutics | Closed |
| Mar 15, 2019 | A multicenter, randomized, double-blind, placebo-controlled phase 3 trial to evaluate efficacy and safety of lenabasum in dermatomyositisLenabasum (JBT-101) | Corbus Pharmaceuticals Inc | Ongoing |
| Nov 4, 2016 | Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis…Octagam 10% | Octapharma Pharmazeutika Produktionsges M B H | Ongoing |
| Nov 8, 2013 | A double blind, randomized, placebo-controlled study to evaluate safety, tolerability, efficacy and preliminary dose-response of BAF312 in patients with active…BAF312 | Novartis Pharmaceuticals | Pending |
| Aug 27, 2026 | LisrayaTreatment of dermatomyositis in adult patients | Priovant Therapeutics, Inc. | Approved |
| Jul 15, 2021 | Octagam 10%Treatment of dermatomyositis in adults | OCTAPHARMA USA, Inc. | Approved |
| Jun 16, 2026 | Reversible and selective small molecule TYK2 inhibitorTreatment of dermatomyositis | Galapagos NV | Designated |
| Oct 17, 2024 | Umbilical cord lining stem cell (ULSC)Treatment of idiopathic inflammatory myositis (including dermatomyositis and polymyositis) | Restem LLC | Designated |
| Mar 29, 2023 | Glucagon like peptide-1 (GLP-1) Elastin like peptide…Treatment of Dermatomyositis (DM) | ImmunoForge Co., Ltd. | Designated |
| Aug 20, 2021 | BegelomabTreatment of dermatomyositis | Adienne SA | Designated |
| Nov 5, 2020 | Recombinant humanized monoclonal antibody (immunoglobulin…Treatment of dermatomyositis | Pfizer Inc. | Designated |
| Oct 22, 2020 | (2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxir…Treatment of dermatomyositis | Kezar Life Sciences, Inc. | Designated |
| Jul 18, 2018 | LenabasumTreatment of dermatomyositis | Corbus Pharmaceuticals, Inc. | Designated |
| Oct 28, 2014 | Sodium thiosulfateTreatment of dermatomyositis | Hope Pharmaceuticals | Designated |
| Oct 13, 1992 | Immune globulin intravenous (human)Treatment of polymyositis/dermatomyositis. | Immuno Clinical Research Corp. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA